AAV delivery of tumor necrosis factor-α short hairpin RNA attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling

Hypertension

Volumn 64, Issue 5, 2014, Pages 1141-1150

  Crosswhite, Patrick ^a   Chen, Kai ^a   Sun, Zhongjie ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Hypertension; Inflammation; Interleukin 6; Macrophage; Phosphodiesterase 1C; Proliferation; Pulmonary; Smooth muscle cells

Indexed keywords

CYCLIC GMP; CYCLINE; INTERLEUKIN 6; PHOSPHODIESTERASE; PHOSPHODIESTERASE 1C; SHORT HAIRPIN RNA; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; SMALL INTERFERING RNA;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; COLD EXPOSURE; CONTROLLED STUDY; GENE SILENCING; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; IN VIVO STUDY; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERIAL REMODELING; PULMONARY HYPERTENSION; RAT; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ADENOVIRIDAE; ADVERSE EFFECTS; ANIMAL; BLOOD PRESSURE; CELL MOTION; COLD; DISEASE MODEL; DRUG EFFECTS; GENETICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MACROPHAGE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANIMALS; BLOOD PRESSURE; CELL MOVEMENT; CELL PROLIFERATION; COLD TEMPERATURE; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MACROPHAGES; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR REMODELING;

EID: 84922394413     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03791     Document Type: Article

References (50)

1. Baker-Blocker A. Winter weather and cardiovascular mortality in Minneapolis-St. Paul. Am J Public Health. 1982;72:261-265.
2. Braga AL, Zanobetti A, Schwartz J. The effect of weather on respiratory and cardiovascular deaths in 12 U.S. cities. Environ Health Perspect. 2002;110:859-863.
3. Hata T, Ogihara T, Maruyama A, Mikami H, Nakamaru M, Naka T, Kumahara Y, Nugent CA. The seasonal variation of blood pressure in patients with essential hypertension. Clin Exp Hypertens A. 1982;4:341-354.
4. Gyllerup S. Cold climate and coronary mortality in Sweden. Int J Circumpolar Health. 2000;59:160-163.
5. Mourtzoukou EG, Falagas ME. Exposure to cold and respiratory tract infections. Int J Tuberc Lung Dis. 2007;11:938-943.
6. Carder M, McNamee R, Beverland I, Elton R, Cohen GR, Boyd J, Agius RM. The lagged effect of cold temperature and wind chill on cardiorespiratory mortality in Scotland. Occup Environ Med. 2005;62:702-710.
7. Keatinge WR, Donaldson GC, Bucher K, Jendritzky G, Cordioli E, Martinelli M, Katsouyanni K, Kunst AE, McDonald C, Näyhä S, Vuori I; Eurowinter Group. Winter mortality in relation to climate. Int J Circumpolar Health. 2000;59:154-159.
8. Keatinge WR. Winter mortality and its causes. Int J Circumpolar Health. 2002;61:292-299.
9. Barr WG, Fahey PJ. Reduction of pulmonary capillary blood volume following cold exposure in patients with Raynaud's phenomenon. Chest. 1988;94:1195-1199.
10. Davis MS, Malayer JR, Vandeventer L, Royer CM, McKenzie EC, Williamson KK. Cold weather exercise and airway cytokine expression. J Appl Physiol (1985). 2005;98:2132-2136.
11. Giesbrecht GG. The respiratory system in a cold environment. Aviat Space Environ Med. 1995;66:890-902.
12. Koskela HO. Cold air-provoked respiratory symptoms: the mechanisms and management. Int J Circumpolar Health. 2007;66:91-100.
13. Greenlees KJ, Tucker A, Robertshaw D, Vader CR. Pulmonary vascular responsiveness in cold-exposed calves. Can J Physiol Pharmacol. 1985;63:131-135.
14. Crosswhite P, Sun Z. Inhibition of phosphodiesterase-1 attenuates coldinduced pulmonary hypertension. Hypertension. 2013;61:585-592.
15. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, Mason RJ. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;280:L39-L49.
16. Gao X, Zhang H, Belmadani S, Wu J, Xu X, Elford H, Potter BJ, Zhang C. Role of TNF-alpha-induced reactive oxygen species in endothelial dysfunction during reperfusion injury. Am J Physiol Heart Circ Physiol. 2008;295:H2242-H2249.
17. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487-501.
18. Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2005;25:2335-2342.
19. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-2821.
20. Tahara N, Kai H, Niiyama H, Mori T, Sugi Y, Takayama N, Yasukawa H, Numaguchi Y, Matsui H, Okumura K, Imaizumi T. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther. 2004;15:1270-1278.
21. van Albada ME, Schoemaker RG, Kemna MS, Cromme-Dijkhuis AH, van Veghel R, Berger RM. The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J. 2005;26:487-493.
22. Zhang TT, Cui B, Dai DZ, Tang XY. Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J Cardiovasc Pharmacol. 2005;46:727-734.
23. Crosswhite P, Sun Z. Ribonucleic acid interference knockdown of interleukin 6 attenuates cold-induced hypertension. Hypertension. 2010;55:1484-1491.
24. Wang X, Skelley L, Cade R, Sun Z. AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage. Gene Ther. 2006;13:1097-1103.
25. Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverseremodeling therapy. Circulation. 2007;115:2331-2339.
26. Wang X, Wang Q, Sun Z. Normal IgG downregulates the intracellular superoxide level and attenuates migration and permeability in human aortic endothelial cells isolated from a hypertensive patient. Hypertension. 2012;60:818-826.
27. Wang X, Skelley L, Wang B, Mejia A, Sapozhnikov V, Sun Z. AAV-based RNAi silencing of NADPH oxidase gp91(phox) attenuates cold-induced cardiovascular dysfunction. Hum Gene Ther. 2012;23:1016-1026.
28. Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension. 2009;54:810-817.
29. Ito T, Okada T, Mimuro J, Miyashita H, Uchibori R, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Sakata Y, Shimada K, Ozawa K. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension. 2007;50:531-536.
30. Ito T, Okada T, Miyashita H, Nomoto T, Nonaka-Sarukawa M, Uchibori R, Maeda Y, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Shimada K, Ozawa K. Interleukin-10 expression mediated by an adenoassociated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res. 2007;101:734-741.
31. Kawakami T, Kanazawa H, Satoh T, Ieda M, Ieda Y, Kimura K, Mochizuki H, Shimada T, Yokoyama C, Ogawa S, Tanabe T, Fukuda K. AAV-PGIS gene transfer improves hypoxia-induced pulmonary hypertension in mice. Biochem Biophys Res Commun. 2007;363:656-661.
32. Zhang B, Shen M, Xu M, Liu LL, Luo Y, Xu DQ, Wang YX, Liu ML, Liu Y, Dong HY, Zhao PT, Li ZC. Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension. Mediators Inflamm. 2012;2012:840737.
33. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):25S-32S.
34. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):13S-24S.
35. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275-285.
36. Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol. 1999;116:174-180.
37. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.
38. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest. 2012;141:210-221.
39. Sun Z. Platelet TLR4: a critical link in pulmonary arterial hypertension. Circ Res. 2014;114:1551-1553.
40. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:281-286.
41. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11:762-774.
42. Zhou X, Chen K, Lei H, Sun Z. Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation [Epub ahead of print, June 5, 2014]. J Am Soc Nephrol. 2014. In press.
43. Vergadi E, Chang MS, Lee C, Liang OD, Liu X, Fernandez-Gonzalez A, Mitsialis SA, Kourembanas S. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation. 2011;123:1986-1995.
44. Sewing AC, Kantores C, Ivanovska J, Lee AH, Masood A, Jain A, McNamara PJ, Tanswell AK, Jankov RP. Therapeutic hypercapnia prevents bleomycin-induced pulmonary hypertension in neonatal rats by limiting macrophage-derived tumor necrosis factor-α. Am J Physiol Lung Cell Mol Physiol. 2012;303:L75-L87.
45. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26:203-234.
46. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA. 2004;101:5634-5639.
47. Sun Z, Lei H, Zhang Z. Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev. 2013;24:433-442.
48. Yazdanpanah B, Wiegmann K, Tchikov V, Krut O, Pongratz C, Schramm M, Kleinridders A, Wunderlich T, Kashkar H, Utermöhlen O, Brüning JC, Schütze S, Krönke M. Riboflavin kinase couples TNF receptor 1 to NADPH oxidase. Nature. 2009;460:1159-1163.
49. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMPdependent protein kinase by cGMP. Am J Physiol. 1994;267(5 Pt 1): C1405-C1413.
50. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93:280-291.